| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Stfa1 |
| Uniprot No | P35175 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-97aa |
| 氨基酸序列 | MSLGGVSEASRATPEIQMIANKVRPQLEAKTNKKYEKFEAVEYKTQVVAGENIFIKMDVGHGCFIHIKVFNGPTGKDNYELHGYQTDKTMDEELTYF |
| 预测分子量 | 16.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Stfa1重组蛋白的模拟参考文献(内容为示例性概括，建议通过学术数据库查证真实文献)：
---
1. **文献名称**: "Recombinant expression and functional characterization of Stfa1 in cysteine protease inhibition"
**作者**: Yamada T. et al.
**摘要**: 本研究报道了通过大肠杆菌系统成功表达并纯化Stfa1重组蛋白，证实其能够有效抑制组织蛋白酶B的活性，并分析了其与底物结合的分子机制。
2. **文献名称**: "Stfa1 modulates apoptosis in cancer cells by regulating caspase activity"
**作者**: Chen L. et al.
**摘要**: 发现Stfa1重组蛋白通过特异性结合caspase-3和caspase-7.延缓肿瘤细胞凋亡进程，提示其在癌症治疗中的潜在调控作用。
3. **文献名称**: "Structural insights into Stfa1-lipid interactions and their role in membrane disruption"
**作者**: Müller R. et al.
**摘要**: 利用X射线晶体学解析Stfa1重组蛋白的三维结构，揭示其N端结构域与磷脂膜的相互作用机制，为解释其抗菌功能提供结构基础。
4. **文献名称**: "Stfa1 as a biomarker for inflammatory bowel disease: Recombinant protein-based detection"
**作者**: Kim S. et al.
**摘要**: 开发基于重组Stfa1蛋白的ELISA检测方法，发现其在炎症性肠病患者血清中显著高表达，提示其作为疾病标志物的可能性。
---
如需具体文献，建议通过PubMed、Web of Science等平台以“Stfa1 recombinant protein”或“Stfa1 function”为关键词检索。
**Background of Stfa1 Recombinant Protein**
Stfa1 (Stefin A1) is a member of the stefin family, a group of cysteine protease inhibitors that regulate proteolytic activity in cells. It is encoded by the *Stfa1* gene in mice and shares homology with human cystatin A, a protein implicated in maintaining protease-antiprotease balance. Stefin A1 primarily inhibits cathepsins, lysosomal cysteine proteases involved in protein degradation, apoptosis, and immune response modulation. Dysregulation of cathepsin activity is linked to pathologies like cancer metastasis, inflammatory disorders, and neurodegenerative diseases, highlighting Stfa1's role in cellular homeostasis.
The recombinant Stfa1 protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells) to ensure high purity and bioactivity. Its structure includes a conserved N-terminal region and a protease-binding epitope, enabling specific interactions with target enzymes. Recombinant Stfa1 is widely used in biochemical assays to study protease inhibition mechanisms, screen therapeutic compounds, or model diseases associated with cathepsin dysregulation.
In research, Stfa1 has been pivotal in exploring skin barrier function, as cystatin deficiencies correlate with skin disorders like psoriasis. It also serves as a tool to investigate tumor progression, as cathepsins promote extracellular matrix remodeling and metastasis. Additionally, Stfa1's neuroprotective potential is under study, given its ability to mitigate excessive proteolysis in neurodegenerative contexts.
Overall, Stfa1 recombinant protein bridges fundamental research and translational applications, offering insights into protease-dependent pathways and therapeutic strategies targeting cathepsin-related diseases.
×
